Cargando…

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Aoli, Yan, Xiao-E, Wu, Hong, Wang, Wenchao, Hu, Chen, Chen, Cheng, Zhao, Zheng, Zhao, Peng, Li, Xixiang, Wang, Li, Wang, Beilei, Ye, Zi, Wang, Jinhua, Wang, Chu, Zhang, Wei, Gray, Nathanael S., Weisberg, Ellen L., Chen, Liang, Liu, Jing, Yun, Cai-Hong, Liu, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342513/ https://www.ncbi.nlm.nih.gov/pubmed/27626175 http://dx.doi.org/10.18632/oncotarget.11951

Ejemplares similares

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
por: Hu, Chen, et al.
Publicado: (2021)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
por: Yu, Kailin, et al.
Publicado: (2017)

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
por: Liu, Feiyang, et al.
Publicado: (2016)

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
por: Mei, Husheng, et al.
Publicado: (2023)

An overview of kinase downregulators and recent advances in discovery approaches
por: Wang, Beilei, et al.
Publicado: (2021)

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus
por: Wang, Junjie, et al.
Publicado: (2023)

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Repurposing of Kinase Inhibitors for Treatment of COVID-19
por: Weisberg, Ellen, et al.
Publicado: (2020)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
por: Hu, Chen, et al.
Publicado: (2022)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
por: Wang, Jin, et al.
Publicado: (2017)

The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR
por: Tan, Biqin, et al.
Publicado: (2020)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
por: Zhao, Zheng, et al.
Publicado: (2014)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
por: Wu, Zijuan, et al.
Publicado: (2022)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation
por: Zhang, Lei, et al.
Publicado: (2016)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
por: Zhang, Qing, et al.
Publicado: (2018)

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences
por: Wang, Aoli, et al.
Publicado: (2020)

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
por: Yin, Zi-Jun, et al.
Publicado: (2018)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5r75oh6f98pdls1lsisvc3mstq